Madrigal Pharmaceuticals Total Revenue

The latest total revenue for MDGL is $1.3B as of June 2026. That compares with $520M in the prior-year period — up 149.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Madrigal Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, MDGL's total revenue moved from $520M to $1.3B — a 149.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Madrigal Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, MDGL currently prints $1.3B for total revenue, while the sector average sits near $110B. That is roughly 98.9% below the sector mean. Large gaps often invite a closer look at Madrigal Pharmaceuticals's growth, margins, and balance sheet.

A total revenue figure of $1.3B for MDGL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting MDGL's total revenue ($1.3B), review year-over-year change from $520M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.